Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00206934
Status:
COMPLETED
Last Update Posted:
2011-09-19
First Post:
2005-09-12
Brief Title:
The Effects of Increased Central Serotonergic Activity on Information Processing
Sponsor:
University of Copenhagen
Organization:
University of Copenhagen
Study Overview
Official Title:
The Effects of Increased Central Serotonergic Activity on Psychophysiological Parameters of Human Information Processing
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is of great clinical relevance to know if selective serotonin re-uptake inhibitors affect information processing Our hypothesis was that aspects of information processing would be disturbed whereas others would improve
Detailed Description:
Numerous studies point to an increased serotoninergic activity in schizophrenia Additionally patients with schizophrenia often show reduced filtering of sensory information which is reflected in reduced P50 suppression and reduced prepulse inhibition of the startle refex PPI Currently the reports in literature on the effects of serotonergic agonists on sensory gating in humans are inconclusive In an initial study performed in our laboratory however we found reduced P50 suppression following administration of imipramine a combined serotonin- and noradrenalin reuptake inhibitor to healthy volunteers This result provides evidence for the involvement of either serotonergic noradrenergic or a combination of both pathways in sensory gating In numerous animal studies however sensory gating is reduced by agonists of 5-HT which suggests a serotonergic rather than a noradrenergic involvement in sensory gating Therefore in a follow-up study the effects of a selective serotonin reuptake inhibitor escitalopram will be investigated on sensory gating parameters of healthy volunteers To further extend the data of our initial study the subjects will additionally be tested for two more psychophysiological parameters of attention that are usually found to be disturbed in patients with schizophrenia ie mismatch negativity and selective attention The design will be a double blind placebo controlled experiment in which a single dose of escitalopram or placebo will be given to healthy non-smoking male volunteers on two occasions separated by at least a week after which the subjects will be tested in the psychophysiological test battery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None